215659-03-3

Basic information

• Product Name: n-PropylMagnesiuMchloride
• Synonyms: Methyl 5-hydroxy-4-Methoxy-3-nitrobenzoate;5-Hydroxy-4-methoxy-2-nitro-benzoic acid methyl ester;Benzoic acid, 5-hydroxy-4-methoxy-2-nitro-, methyl ester
• CAS NO: 215659-03-3
• Molecular Formula: C₉H₉NO₆
• Molecular Weight: 102.84568
• Mol File: 215659-03-3.mol

Chemical Properties

• Boiling Point: 419.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.405±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 6.20±0.24(Predicted)
• CAS DataBase Reference: n-PropylMagnesiuMchloride(CAS DataBase Reference)
• NIST Chemistry Reference: n-PropylMagnesiuMchloride(215659-03-3)
• EPA Substance Registry System: n-PropylMagnesiuMchloride(215659-03-3)

Safety Data

• Hazardous Substances Data: 215659-03-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
n-Propylmagnesium chloride is used as a reagent in organic synthesis for its ability to form carbon-carbon bonds through Grignard reactions. It is particularly useful in the synthesis of complex organic molecules and the formation of new chemical entities.
Used in Pharmaceutical Production:
In the pharmaceutical industry, n-Propylmagnesium chloride is used as a reagent in the synthesis of various pharmaceutical compounds. Its reactivity allows for the creation of a wide range of organic compounds, contributing to the development of new drugs and therapeutic agents.
Used in Catalyst Applications:
n-Propylmagnesium chloride is employed as a catalyst in industrial processes, where its reactivity can enhance the efficiency of chemical reactions and improve the overall yield of desired products.
Used in Fine Chemicals Production:
In the production of fine chemicals, n-Propylmagnesium chloride is used as a reagent to create specialty chemicals with specific properties and applications. Its versatility in forming carbon-carbon bonds makes it valuable in the synthesis of a variety of fine chemicals.
Used in Research and Development:
n-Propylmagnesium chloride is utilized in research and development settings to explore new chemical reactions and develop innovative synthetic routes for the production of novel compounds. Its reactivity and ability to form carbon-carbon bonds make it a valuable tool in advancing the field of organic chemistry.

Upstream product

• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 67-56-1 methanol 
• 26791-93-5 methyl 4,5-dimethoxy-2-nitrobenzoate 
• 100905-33-7 ethyl 2-nitro-4,5-dimethoxybenzoate 
• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 

Downstream Products

• 164161-49-3 methyl 5-(benzyloxy)-4-methoxy-2-nitrobenzoate 
• 1146162-35-7 methyl 4-methoxy-5-(2-methoxyethoxy)-2-nitrobenzoate 
• 214472-37-4 4-methoxy-5-(3-morpholinylpropoxy)-2-nitrobenzoic acid methyl ester 
• 1188906-89-9 methyl 5-(2-chloroethoxy)-4-methoxy-2-nitrobenzoate 
• 380844-24-6 methyl 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzoate 
• 307353-95-3 4-chloro-6-hydroxy-7-methoxyquinoline-3-carbonitrile 
• 214472-41-0 methyl 5-(3-morpholinopropoxy)-2-amino-4-methoxy-benzoate 
• 199327-61-2 7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one 
• 214470-90-3 5-ethoxy-4-methoxy-2-nitrobenzoic acid methyl ester 
• 214470-85-6 2-amino-5-ethoxy-4-methoxybenzoic acid methyl ester 
• 1188911-78-5 C₁₇H₁₇N₃O₃ 
• 1188908-27-1 4-(3-aminophenoxy)-7-methoxyquinazolin-6-ol 
• 1188908-26-0 C₂₂H₁₉N₃O₃ 
• 577728-29-1 C₁₁H₁₂N₂O₃ 

Relevant articles and documents

Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity

ERK1/2 inhibitors have attracted special attention concerning the ability of circumventing cases of innate or log-term acquired resistance to RAF and MEK kinase inhibitors. Based on the 4-aminoquinazoline pharmacophore of kinases, herein we describe the synthesis of 4-aminoquinazoline derivatives bearing a 1,2,3-triazole stable core to bridge different aromatic and heterocyclic rings using copper-catalysed azide-alkyne cycloaddition reaction (CuAAC) as a Click Chemistry strategy. The initial screening of twelve derivatives in tumoral cells (CAL-27, HN13, HGC-27, and BT-20) revealed that the most active in BT-20 cells (25a, IC50 24.6 μM and a SI of 3.25) contains a more polar side chain (sulfone). Furthermore, compound 25a promoted a significant release of lactate dehydrogenase (LDH), suggesting the induction of cell death by necrosis. In addition, this compound induced G0/G1 stalling in BT-20 cells, which was accompanied by a decrease in the S phase. Western blot analysis of the levels of p-STAT3, p-ERK, PARP, p53 and cleaved caspase-3 revealed p-ERK1/2 and p-STA3 were drastically decreased in BT-20 cells under 25a incubation, suggesting the involvement of these two kinases in the mechanisms underlying 25a-induced cell cycle arrest, besides loss of proliferation and viability of the breast cancer cell. Molecular docking simulations using the ERK-ulixertinib crystallographic complex showed compound 25a could potentially compete with ATP for binding to ERK in a slightly higher affinity than the reference ERK1/2 inhibitor. Further in silico analyses showed comparable toxicity and pharmacokinetic profiles for compound 25a in relation to ulixertinib.

PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ?-CELL PATHOGENESIS AND TREATING DIABETES

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and/or reversing, returning blood glucose concentration to a normal level in a diabetic.

HETEROCYCLIC INHIBITORS OF TYROSINE KINASE

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.

Process for preparation of substituted P-aminophenol

The present invention is related to a process of preparing substituted p-aminophenol compound of formula (I) or a salt thereof,

Stereoselective Synthesis of Bicyclic Heterocycles

The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have va

Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)

Continued examination of substituted 6-arylquinazolin-4-amines as Clk4 inhibitors resulted in selective inhibitors of Clk1, Clk4, Dyrk1A and Dyrk1B. Several of the most potent inhibitors were validated as being highly selective within a comprehensive kino

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia

Utilizing structure-based virtual library design and scoring, a novel chimeric series of phosphodiesterase 10A (PDE10A) inhibitors was discovered by synergizing binding site interactions and ADME properties of two chemotypes. Virtual libraries were docked and scored for potential binding ability, followed by visual inspection to prioritize analogs for parallel and directed synthesis. The process yielded highly potent and selective compounds such as 16. New X-ray cocrystal structures enabled rational design of substituents that resulted in the successful optimization of physical properties to produce in vivo activity and to modulate microsomal clearance and permeability.

Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline

A method of synthesizing 6,7-substituted 4-anilino quinazoline employs 3,4-substituted benzoic acid as an initial reactant, and the 6,7-substituted 4-anilino quinazoline is obtained by an esterifying step, a nitrating step, a reducing step, a cyclizing step, and an one-pot reaction. In the above method, the initial reactant has low cost and yield. of the 6,7-substituted 4-anilino quinazoline is high, therefore, production cost can be reduced effectively, and competitive power of the product of the 6,7-substituted 4-anilino quinazoline can be improved.

A PROCESS FOR THE PREPARATION OF GEFITINIB

The present invention provides an improved, industrial advantageous process for the preparation of gefitinib of formula (I), and its pharmaceutically acceptable salts thereof in high yield and purity.

THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.